Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Pearl Huang
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
therapies targeting the peripheral nervous system
|
| gptkbp:focusesOn |
immunology
neurobiology cancer therapeutics |
| gptkbp:foundedYear |
2017
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cygnal Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableFor |
pioneering exoneural biology
|
| gptkbp:parentCompany |
gptkb:Flagship_Pioneering
|
| gptkbp:website |
https://cygnaltx.com/
|
| gptkbp:bfsParent |
gptkb:Fine_Structure_Ventures
|
| gptkbp:bfsLayer |
7
|